Latest news with #OfficialActionIndicated
Business Upturn
8 hours ago
- Business
- Business Upturn
OneSource Specialty Pharma shares jump 3% after USFDA grants VAI classification for its Bangalore facility
By Aman Shukla Published on June 10, 2025, 09:22 IST Shares of OneSource Specialty Pharma Ltd jumped 3% in morning trade on June 10 after the company announced that its flagship facility in Bangalore received a 'Voluntary Action Indicated' (VAI) classification from the U.S. Food and Drug Administration (USFDA). As of 9:21 AM, the shares were trading 3.61% higter at Rs 2,002.70. The classification follows a routine USFDA inspection conducted from March 20 to March 28, 2025. At the end of the inspection, the agency issued a Form 483 with four observations. The company responded with a comprehensive corrective action plan. After reviewing the response, the USFDA designated the outcome as VAI, indicating that while issues were noted, they were not serious enough to trigger regulatory or enforcement action. The VAI status also confirms that the inspection is now officially closed. The company did not disclose the specific details of the observations, but emphasized that the facility remains integral to its core manufacturing and development operations. A VAI classification is generally seen as a positive regulatory outcome, especially compared to more severe classifications like 'Official Action Indicated' (OAI). Investors reacted favorably to the news, pushing the stock higher. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
14-05-2025
- Business
- Business Upturn
Piramal Pharma Q4FY25 results: Net profit jumps 52% YoY to Rs 154 crore; revenue up 8% to Rs 2,754 crore
Piramal Pharma Limited (PPL) reported a robust financial performance for the fiscal year ended March 31, 2025, with net profit rising over 411% to ₹91 crore, as compared to ₹18 crore in FY24. The growth was driven by strong momentum in its Contract Development and Manufacturing Organization (CDMO) business and operational efficiency across verticals. The company's revenue from operations stood at ₹9,151 crore, marking a 12% year-on-year growth, while EBITDA increased by 15% to ₹1,580 crore. EBITDA margin remained steady at 17%. For the fourth quarter (Q4FY25), revenue rose 8% YoY to ₹2,754 crore, with net profit at ₹154 crore, up from ₹101 crore in the same period last year. CDMO leads the performance; quality track record maintained The CDMO segment, which includes commercial manufacturing of on-patent molecules, clocked a 15% annual revenue growth to ₹5,447 crore. The business benefited from increased innovation-related work, which rose to 54% of CDMO revenues, and over 50% YoY growth in commercial revenues. The company cleared 36 regulatory inspections and 165 customer audits in FY25 without any major observations, reinforcing its zero OAI (Official Action Indicated) status maintained since 2011. Strong showing in generics and consumer healthcare The Complex Hospital Generics (CHG) business, with revenue of ₹2,633 crore, saw a notable boost from inhalation anesthetics and Baclofen. The company retained its #1 position in the US market for Sevoflurane, with a 44% share. The India Consumer Healthcare (ICH) segment crossed a strategic revenue milestone of ₹1,000 crore, with power brands contributing 49% of total ICH revenue. The company launched 21 new products and 31 new SKUs during the year, and e-commerce sales surged 39% YoY. Balance sheet healthy; net debt under control PPL maintained a Net Debt to EBITDA ratio of 2.7x, well below its previous 5.6x level. Net debt declined to ₹4,199 crore, from ₹3,932 crore in FY24. The company also reported a total equity of ₹8,125 crore. Looking ahead: Innovation and scale Chairperson Nandini Piramal said FY25 was 'a steady year for the company,' highlighting performance across all business segments and reiterating the company's ambition to become a $2 billion revenue company with 25% EBITDA margins and high return on capital employed (ROCE). 'We crossed $1 billion in revenues with 12% YoY growth and 5x increase in net profits. Our focus on innovation, operational excellence, and expansion in the US and emerging markets has placed us on a strong trajectory for sustainable growth,' she added.
Business Upturn
12-05-2025
- Business
- Business Upturn
Top stocks to watch today, May 12: SBI, Yes Bank, Adani Power, Swiggy, Prestige Estates, ABB India and more
By Aman Shukla Published on May 12, 2025, 08:23 IST Indian benchmark indices, Sensex and Nifty50, are expected to open on a positive note today, supported by improving geopolitical sentiment as the India-Pakistan understanding remains intact. Here's a look at key stocks likely to remain in focus: Key Stocks to Watch SBI, Yes Bank : State Bank of India and a group of banks are set to sell a 20% stake in Yes Bank to Sumitomo Mitsui Banking Corporation. Adani Power : Received a Letter of Award from Uttar Pradesh Power Corporation to supply 1,500 MW of electricity. BEML : Allotted approximately 148 acres of land by the Madhya Pradesh government. Prestige Estates : Announced a joint development agreement with Arihant for real estate projects in Chennai. Puravankara : Formed a joint venture for 24.59-acre land in Bengaluru with an estimated gross development value (GDV) of ₹3,300 crore. Birla Corporation : Reported better-than-expected Q4 results with a 7% quarter-on-quarter rise in realizations. Solara Active Pharma : Received Form 483 with zero observations from the US FDA for its Ambernath manufacturing facility. Novartis India : Posted a year-on-year revenue growth of 3%; operating margin improved to 28.5% from 14.2%. CE Info Systems : Reported a 46% increase in EBITDA and a 34.2% YoY rise in revenue. Atul Auto : EBITDA increased 14.5%, while revenue grew 31.9% YoY. Eveready Industries : EBITDA rose 2.4% YoY, with a slight margin decline to 8.6% from 9%. Aarti Pharma : Reported 24% growth in EBITDA, with operating margin rising to 25.8% from 23.2%. Triveni Turbines : Posted 34% YoY growth in EBITDA; margin improved to 22.4% from 19.6%. Borosil Renewables : Turned EBITDA positive; revenue increased 32% YoY. Pharma : 'To sign an exec order to reduce drug prices,' Trump on Truth Social Manappuram Finance : NII declined 3% YoY; other expenses rose 21%. ABB India : Q1CY25 results missed estimates, though EBITDA margin improved by 8 basis points YoY. Thermax : Q4 earnings fell below expectations, citing soft growth in industrial infrastructure and green solutions. Glenmark : The US FDA classified its Indore manufacturing facility as 'Official Action Indicated'. Bank of India : Net interest margin declined to 2.61% from 2.80% QoQ; net NPA rose to 1.22% from 0.85%. Navin Fluorine : Reported results in line with estimates; margin rose by 720 basis points YoY. Swiggy : Reported overall EBITDA pressure, primarily due to losses in its quick-commerce business. GE Shipping : Revenue declined 18.3%, while profit dropped 60% YoY. Electrosteel Castings : Reported a 48.7% decline in EBITDA; margin dropped to 9.45% from 15.5%. Apollo Pipes: EBITDA fell 2%; operating margin decreased to 7.65% from 9.62%. ABB IndiaAdani PowerPrestige EstatesSBIStock MarketSwiggyYes Bank Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
